Skip to main content

Advertisement

SpringerLink
Log in

Antiplatelet Agents in the Prevention of Cardiovascular Morbidity and Mortality in Older Patients With Vascular Disease

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Antiplatelet drugs have been demonstrated to reduce the incidence of myocardial infarction (MI), stroke or vascular death in patients with vascular disease. There are no data suggesting that antiplatelet therapy acts differently in older people than in younger people and recommendations based on randomised clinical trials are probably generalisable to older people.

Aspirin (acetylsalicylic acid) has been shown to reduce the incidence of nonfatal MI, nonfatal stroke and vascular death in patients with acute MI, a previous MI, angina pectoris or peripheral occlusive arterial disease (POAD), and to reduce cardiovascular morbidity and mortality in patients with a prior ischaemic stroke or transient ischaemic attack (TIA). It has also been shown to reduce the incidence of thrombus formation after coronary artery bypass graft surgery and percutaneous transluminal angioplasty, and in patients with atrial fibrillation and heart valve replacements. Deep vein thrombosis and pulmonary embolism after surgery are also prevented by aspirin. The available data allows the following recommendations to be made. Aspirin 160 to 325mg daily should be administered to older men and women without contraindications to aspirin who have acute MI, prior MI, unstable or stable angina pectoris, ischaemic stroke, TIA or POAD, and continued indefinitely to reduce the risk of MI, stroke or vascular death. Aspirin should be started in patients before or immediately after revascularisation, and after heart valve replacement. Older men and women with nonvalvular atrial fibrillation who have contraindications to oral anticoagulant therapy but no contraindications to aspirin should be treated with aspirin 325mg daily. It is reasonable to treat older men and women without contraindications to aspirin with aspirin 160 to 325mg daily if they are at high risk for developing new coronary events.

The incidence of stroke, MI or vascular death in patients after a stroke or TIA is reduced by ticlopidine. Therefore, ticlopidine 250mg twice daily may be used in older men and women with a history of stroke or TIA who do not respond to or who cannot tolerate aspirin. Patients at high risk for coronary artery stent thrombosis benefit from combined therapy with aspirin plus ticlopidine. The annual incidence of ischaemic stroke, MI or vascular death was significantly reduced by Clopidogrel in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial. Therefore, Clopidogrel 75mg daily may be used in older men and women with symptomatic atherosclerosis who do not respond to or who cannot tolerate aspirin to reduce the incidence of ischaemic stroke, MI or vascular death.

It should be noted that the acquisition cost for either ticlopidine or clopidogrel is considerably greater than that for aspirin. Most data indicate that the combination of aspirin and dipyridamole is not more effective than aspirin alone in preventing vascular events, and available data do not support the use of sulfinpyrazone in patients with vascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aronow WS. Risk factors for coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in elderly persons. In: Aronow WS, Stemmer EA, Wilson SE, editors. Vascular disease in the elderly. Armonk (NY): Futura Publishing Co., 1997: 81–104

    Google Scholar 

  2. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Article  Google Scholar 

  3. FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316: 1247–57

    Article  PubMed  CAS  Google Scholar 

  4. Diener HC, Cunha L, Forbes C, et al. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13

    Article  PubMed  CAS  Google Scholar 

  5. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–75

    Article  PubMed  CAS  Google Scholar 

  6. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624–32

    Article  PubMed  CAS  Google Scholar 

  7. Hardisty RM, Powling MJ, Nokes TJ. The action of ticlopidine on human platelets: studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990; 64: 145–50

    Google Scholar 

  8. Mills DC, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADPanalogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430–6

    Article  PubMed  CAS  Google Scholar 

  9. Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349–60

    Google Scholar 

  10. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: patterns of use and outcomes. Circulation 1995; 92: 2841–7

    Article  PubMed  CAS  Google Scholar 

  11. Goldstein RE, Andrews M, Hall WJ, et al. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996; 28: 326–30

    Article  PubMed  CAS  Google Scholar 

  12. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350: 389–96

    Article  Google Scholar 

  13. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHAguidelines for the management of patients with acute myocardial infarction: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 1996; 94: 2341–50

    Article  PubMed  CAS  Google Scholar 

  14. Aronow WS. Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc 1998; 46: 615–6

    PubMed  CAS  Google Scholar 

  15. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcome. Ann Intern Med 1996; 124: 292–8

    PubMed  CAS  Google Scholar 

  16. Lewis Jr HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a veterans administration cooperative study. N Engl J Med 1983; 309: 396–403

    Article  PubMed  Google Scholar 

  17. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–11

    Article  PubMed  CAS  Google Scholar 

  18. Wallentin LC, the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991; 18: 1587–93

    Article  PubMed  CAS  Google Scholar 

  19. Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. Am J Cardiol 1998; 81: 678–81

    Article  PubMed  CAS  Google Scholar 

  20. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421–5

    Article  PubMed  CAS  Google Scholar 

  21. Ridker PM, Manson JE, Gaziano M, et al. Low-dose aspirin for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835–9

    PubMed  CAS  Google Scholar 

  22. Harpaz D, Benderly M, Goldbourt U, et al. Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Am J Cardiol 1996; 78: 1215–9

    Article  PubMed  CAS  Google Scholar 

  23. Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982; 307: 73–8

    Article  PubMed  CAS  Google Scholar 

  24. Lorenz RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation. Lancet 1984; I: 1261–4

    Article  Google Scholar 

  25. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a veterans administration cooperative study. Circulation 1988; 77: 1324–32

    Article  PubMed  CAS  Google Scholar 

  26. van der Meer J, de la Riviere AB, van Gilst WH, et al. Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. J Am Coll Cardiol 1994; 24: 1181–8

    Article  PubMed  Google Scholar 

  27. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76: 125–34

    Article  PubMed  CAS  Google Scholar 

  28. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65: 422–6

    Article  PubMed  CAS  Google Scholar 

  29. Minar E, Ahmadi A, Koppensteiner R, et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995; 91: 2167–73

    Article  PubMed  CAS  Google Scholar 

  30. The Swedish Aspirin Low-Dose Trial (SALT) Collaborative Group. SALT of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–9

    Article  Google Scholar 

  31. International Stroke Trial Collaborative Group. The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569–81

    Article  Google Scholar 

  32. Chinese Acute Stroke Trial (CAST) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641–9

    Article  Google Scholar 

  33. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62

    Google Scholar 

  34. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–57

    Article  Google Scholar 

  35. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996; 348: 633–8

    Article  Google Scholar 

  36. Turpie AGG, Gent M, Laupacis A, et al. Acomparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524–9

    Article  PubMed  CAS  Google Scholar 

  37. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet 1985; I: 415–9

    Article  Google Scholar 

  38. Ranke C, Hecker H, Creutzig A, et al. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 1993; 87: 1873–9

    Article  PubMed  CAS  Google Scholar 

  39. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis in pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235–46

    Article  Google Scholar 

  40. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–81

    Article  PubMed  CAS  Google Scholar 

  41. Steering Committee of the Physicians Health Study Research Group. Final report on the aspirin component of the ongoing physicians health study. N Engl J Med 1989; 321: 129–35

    Article  Google Scholar 

  42. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313–6

    Article  PubMed  CAS  Google Scholar 

  43. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266: 521–7

    Article  PubMed  CAS  Google Scholar 

  44. UK-TIA Study Group. United Kingdom transient ischaemia attack aspirin trial interim results. BMJ 1988; 296: 316–20

    Article  Google Scholar 

  45. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998; 114: 470S–88

    Article  PubMed  CAS  Google Scholar 

  46. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989; I: 1215–20

    Article  Google Scholar 

  47. Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7

    Article  PubMed  CAS  Google Scholar 

  48. Clopidogrel. Med Lett Drugs Ther 1998; 40(1028): 59–60

    Google Scholar 

  49. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990; 82: 17–26

    Article  PubMed  CAS  Google Scholar 

  50. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish ticlopidine multicentre study. J Intern Med 1990; 227: 301–8

    Article  PubMed  CAS  Google Scholar 

  51. Arcan JC, Blanchard J, Boissel JP, et al. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988; 39: 802–11

    Article  PubMed  CAS  Google Scholar 

  52. Blanchard J, Carreras LO, Kindermans M. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol 1993; 35: 523–8

    Google Scholar 

  53. Chevigne M, David JL, Rigo P, et al. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg 1984; 37: 371–8

    Article  PubMed  CAS  Google Scholar 

  54. Limet R, David JL, Magotteaux P, et al. Prevention of aortacoronary bypass graft occlusion: beneficial effects of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987; 94: 773–83

    PubMed  CAS  Google Scholar 

  55. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337: 1726–31

    Article  PubMed  CAS  Google Scholar 

  56. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998; 98: 1597–603

    Article  PubMed  CAS  Google Scholar 

  57. Schomig A, Neumann F-J, Kastrati A, et al. Arandomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–9

    Article  PubMed  CAS  Google Scholar 

  58. Schuhlen H, Hadamitzky M, Walter H, et al. Particular benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary stent placement: analysis of a prospective risk stratification protocol in the ISAR trial [abstract]. Circulation 1996; 94Suppl. I: I–257

    Google Scholar 

  59. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 337: 1665–71

    Article  Google Scholar 

  60. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39

    Article  Google Scholar 

  61. Roden DM. Cardiovascular and renal advisory panel of the FDA. Circulation 1998; 97: 1107

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hebrew Hospital Home, 801 Co-op City Blvd., Bronx, New York, 10475, USA

    Wilbert S. Aronow (Medical Director)

  2. The Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, USA

    Wilbert S. Aronow (Medical Director)

Authors
  1. Wilbert S. Aronow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wilbert S. Aronow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aronow, W.S. Antiplatelet Agents in the Prevention of Cardiovascular Morbidity and Mortality in Older Patients With Vascular Disease. Drugs Aging 15, 91–101 (1999). https://doi.org/10.2165/00002512-199915020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915020-00003

Keywords

Search

Navigation